These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18774412)

  • 21. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir update.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
    Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
    AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
    [No Abstract]   [Full Text] [Related]  

  • 25. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
    Young J; Xiao Y; Moodie EE; Abrahamowicz M; Klein MB; Bernasconi E; Schmid P; Calmy A; Cavassini M; Cusini A; Weber R; Bucher HC;
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):413-21. PubMed ID: 25932884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?
    Marchetti G; Casana M; Tincati C; Bellistrì GM; Monforte Ad
    Clin Infect Dis; 2008 Dec; 47(11):1495-6. PubMed ID: 18986270
    [No Abstract]   [Full Text] [Related]  

  • 31. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
    Dorjee K; Choden T; Baxi SM; Steinmaus C; Reingold AL
    Int J Antimicrob Agents; 2018 Nov; 52(5):541-553. PubMed ID: 30040992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abacavir at last.
    Gilden D
    GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abacavir sulfate.
    Porche DJ
    J Assoc Nurses AIDS Care; 2000; 11(6):72-5. PubMed ID: 11082806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.